Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL LEE SOLIS

Allopathic & Osteopathic Physicians Family Medicine

NPI
1033191424
CMS profile
1725
Location
MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$7,761.68

191 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,446.00 4
Food and Beverage $3,207.14 183
Travel and Lodging $1,102.54 3
Education $6.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL LEE SOLIS

NPI 1033191424 · CMS profile ID 1725

Allopathic & Osteopathic Physicians / Family Medicine

MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033191424?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL LEE SOLIS, NPI 1033191424, CMS profile ID 1725. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033191424?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOEL LEE SOLIS, NPI 1033191424, CMS profile ID 1725. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033191424?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOEL LEE SOLIS, NPI 1033191424, CMS profile ID 1725, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1033191424?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

191 matching records · $7,761.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 191 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 191.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $13.6005/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662518311 CMS
Teva Pharmaceuticals USA, Inc. $2.9705/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697709617 CMS
Horizon Therapeutics plc $13.6105/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691501637 CMS
AstraZeneca Pharmaceuticals LP $13.1705/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685720969 CMS
Janssen Pharmaceuticals, Inc $12.9105/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659306529 CMS
ARBOR PHARMACEUTICALS, INC. $16.2305/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697357539 CMS
Shire North American Group Inc $15.1905/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637922009 CMS
Teva Pharmaceuticals USA, Inc. $17.0305/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697777297 CMS
AstraZeneca Pharmaceuticals LP $13.8105/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685175883 CMS
SANOFI-AVENTIS U.S. LLC $18.8105/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694019947 CMS
Radius Health, Inc. $16.5005/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683943031 CMS
Lilly USA, LLC $6.4305/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657910881 CMS
Horizon Therapeutics plc $1.6805/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691501629 CMS
Horizon Therapeutics plc $3.7305/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691501633 CMS
Novo Nordisk Inc $14.3005/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669590247 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2405/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684944781 CMS
AstraZeneca Pharmaceuticals LP $448.0405/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685272695 CMS
AstraZeneca Pharmaceuticals LP $26.8905/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685325691 CMS
AstraZeneca Pharmaceuticals LP $14.7905/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685544103 CMS
AstraZeneca Pharmaceuticals LP $56.4705/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685656721 CMS
AstraZeneca Pharmaceuticals LP $121.0105/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685718847 CMS
AstraZeneca Pharmaceuticals LP $36.3005/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685803905 CMS
AstraZeneca Pharmaceuticals LP $191.8005/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685823701 CMS
PFIZER INC. $15.8304/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673314713 CMS
AstraZeneca Pharmaceuticals LP $14.9304/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685582515 CMS
ARBOR PHARMACEUTICALS, INC. $9.5204/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697357527 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $103.9104/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700227297 CMS
Teva Pharmaceuticals USA, Inc. $11.9704/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697793779 CMS
Novo Nordisk Inc $8.1304/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682496871 CMS
Amarin Pharma Inc. $14.6404/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699125937 CMS
Lilly USA, LLC $10.8404/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657910873 CMS
Lilly USA, LLC $0.7704/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657897027 CMS
Amgen Inc. $21.6304/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662518323 CMS
AbbVie, Inc. $13.3404/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647802073 CMS
AbbVie, Inc. $14.1804/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647802075 CMS
AstraZeneca Pharmaceuticals LP $123.1804/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685323755 CMS
Romark Laboratories, LC $20.5904/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676574843 CMS
AstraZeneca Pharmaceuticals LP $384.0004/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685657337 CMS
Lilly USA, LLC $12.7404/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657914283 CMS
SANOFI-AVENTIS U.S. LLC $21.8104/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693965653 CMS
Philips Electronics North America Corporation $13.3804/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684083121 CMS
AstraZeneca Pharmaceuticals LP $81.5203/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685987297 CMS
Romark Laboratories, LC $21.8403/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676574841 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.4603/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700227305 CMS
Lilly USA, LLC $2.6203/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657910877 CMS
Radius Health, Inc. $13.0203/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683942989 CMS
Novo Nordisk Inc $16.1403/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703514101 CMS
ARBOR PHARMACEUTICALS, INC. $10.2703/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697357519 CMS
AstraZeneca Pharmaceuticals LP $12.5803/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685151757 CMS
AstraZeneca Pharmaceuticals LP $384.0003/19/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685977639 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,761.68 191
PY2020 $7,205.43 168
PY2021 $20,754.80 220
PY2022 $23,360.47 236
PY2023 $92,665.42 311
PY2024 $92,682.35 308
PY2025 $79,285.08 249

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,229,829.00 257
PY2024 Principal investigator $612,081.91 17
PY2023 Principal investigator $1,023,770.95 124
PY2022 Principal investigator $7,842,177.92 536
PY2021 Principal investigator $5,854,572.51 514
PY2020 Principal investigator $3,011,098.66 169
PY2019 Principal investigator $1,219,400.75 189

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

257 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $2,522.85 12/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713688
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 12/17/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713376
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 12/17/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713378
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713756
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 12/17/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713758
Principal investigator 1 Boehringer Ingelheim International GmbH $23,177.00 12/10/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713368
Principal investigator 1 Boehringer Ingelheim International GmbH $15,180.00 12/10/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713370
Principal investigator 1 Boehringer Ingelheim International GmbH $12,397.00 12/10/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713372
Principal investigator 1 Boehringer Ingelheim International GmbH $12,397.00 12/04/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713716
Principal investigator 1 Boehringer Ingelheim International GmbH $23,177.00 12/04/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713722
Principal investigator 1 Boehringer Ingelheim International GmbH $3,002.40 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713690
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713692
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713694
Principal investigator 1 Boehringer Ingelheim International GmbH $2,654.90 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713696
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713698
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713700
Principal investigator 1 Boehringer Ingelheim International GmbH $2,654.90 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713702
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713704
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713706
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713708
Principal investigator 1 Boehringer Ingelheim International GmbH $910.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713710
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713712
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713714
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713718
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713720
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713724
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713726
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713728
Principal investigator 1 Boehringer Ingelheim International GmbH $4.47 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713730
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713732
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713734
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713736
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713738
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713740
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713742
Principal investigator 1 Boehringer Ingelheim International GmbH $2,481.15 12/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713744
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 12/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713366
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 12/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713374
Principal investigator 1 Boehringer Ingelheim International GmbH $910.00 11/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713358
Principal investigator 1 Boehringer Ingelheim International GmbH $585.00 11/12/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713352
Principal investigator 1 Boehringer Ingelheim International GmbH $670.00 11/12/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713360
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 11/10/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713354
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 11/10/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713362
Principal investigator 1 Boehringer Ingelheim International GmbH $41,624.00 11/06/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713356
Principal investigator 1 Boehringer Ingelheim International GmbH $22,264.00 11/06/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713364
Principal investigator 1 Boehringer Ingelheim International GmbH $41,624.00 11/06/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713650
Principal investigator 1 Boehringer Ingelheim International GmbH $16,951.00 11/06/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713660
Principal investigator 1 Boehringer Ingelheim International GmbH $31,691.00 11/06/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713670
Principal investigator 1 Boehringer Ingelheim International GmbH $22,264.00 11/06/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713678
Principal investigator 1 Boehringer Ingelheim International GmbH $520.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713642
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713644
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713646
Principal investigator 1 Boehringer Ingelheim International GmbH $2,411.65 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713648
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713652
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713654
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713656
Principal investigator 1 Boehringer Ingelheim International GmbH $670.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713658
Principal investigator 1 Boehringer Ingelheim International GmbH $2,564.55 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713662
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713664
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713666
Principal investigator 1 Boehringer Ingelheim International GmbH $2,668.80 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713668
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713672
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713674
Principal investigator 1 Boehringer Ingelheim International GmbH $820.10 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713676
Principal investigator 1 Boehringer Ingelheim International GmbH $3,002.40 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713680
Principal investigator 1 Boehringer Ingelheim International GmbH $425.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713682
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713684
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/05/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713686
Principal investigator 1 Boehringer Ingelheim International GmbH $2,400.00 10/29/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713344
Principal investigator 1 Boehringer Ingelheim International GmbH $20,339.00 10/29/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713348
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 10/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713746
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 10/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713748
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 10/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713750
Principal investigator 1 Boehringer Ingelheim International GmbH $126.10 10/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713752
Principal investigator 1 Boehringer Ingelheim International GmbH $1.00 10/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713754
Principal investigator 1 Boehringer Ingelheim International GmbH $15,180.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713590
Principal investigator 1 Boehringer Ingelheim International GmbH $1,400.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713592
Principal investigator 1 Boehringer Ingelheim International GmbH $1,100.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713594
Principal investigator 1 Boehringer Ingelheim International GmbH $22,295.61 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713596
Principal investigator 1 Boehringer Ingelheim International GmbH $10,879.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713598
Principal investigator 1 Boehringer Ingelheim International GmbH $55.60 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713602
Principal investigator 1 Boehringer Ingelheim International GmbH $5,313.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713604
Principal investigator 1 Boehringer Ingelheim International GmbH $97.30 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713608
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713612
Principal investigator 1 Boehringer Ingelheim International GmbH $97.30 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713616
Principal investigator 1 Boehringer Ingelheim International GmbH $139.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713618
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713620
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713624
Principal investigator 1 Boehringer Ingelheim International GmbH $20,339.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713626
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713628
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713630
Principal investigator 1 Boehringer Ingelheim International GmbH $110.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713632
Principal investigator 1 Boehringer Ingelheim International GmbH $97.30 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713634
Principal investigator 1 Boehringer Ingelheim International GmbH $12,144.00 10/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713636
Principal investigator 1 Boehringer Ingelheim International GmbH $2,010.00 10/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713638
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 10/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713640
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 10/17/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713340
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/17/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713346
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/17/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713350
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713336
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713338
Principal investigator 1 Boehringer Ingelheim International GmbH $780.00 10/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713342
Principal investigator 1 Boehringer Ingelheim International GmbH $22,295.60 10/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713600
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713606
Principal investigator 1 Boehringer Ingelheim International GmbH $780.00 10/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713610
Principal investigator 1 Boehringer Ingelheim International GmbH $22,295.60 10/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713614
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713622
Principal investigator 1 Boehringer Ingelheim International GmbH $28,380.00 09/26/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713330
Principal investigator 1 Boehringer Ingelheim International GmbH $22,751.52 09/26/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713560
Principal investigator 1 Boehringer Ingelheim International GmbH $28,380.00 09/26/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713564
Principal investigator 1 Boehringer Ingelheim International GmbH $691.53 09/26/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713570
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713326
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713328
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713550
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713552
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713554
Principal investigator 1 Boehringer Ingelheim International GmbH $19.54 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713556
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713558
Principal investigator 1 Boehringer Ingelheim International GmbH $1,235.00 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713562
Principal investigator 1 Boehringer Ingelheim International GmbH $425.00 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713566
Principal investigator 1 Boehringer Ingelheim International GmbH $725.00 09/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713568
Principal investigator 1 Boehringer Ingelheim International GmbH $1,300.00 09/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713332
Principal investigator 1 Boehringer Ingelheim International GmbH $8.56 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713572
Principal investigator 1 Boehringer Ingelheim International GmbH $51.44 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713574
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713576
Principal investigator 1 Boehringer Ingelheim International GmbH $2.98 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713578
Principal investigator 1 Boehringer Ingelheim International GmbH $42.86 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713580
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713582
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713584
Principal investigator 1 Boehringer Ingelheim International GmbH $196.00 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713586
Principal investigator 1 Boehringer Ingelheim International GmbH $36.00 09/09/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713588
Principal investigator 1 Boehringer Ingelheim International GmbH $22,011.00 09/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713334
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 08/28/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713542
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 08/28/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713544
Principal investigator 1 Boehringer Ingelheim International GmbH $41,151.00 08/14/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713540
Principal investigator 1 Boehringer Ingelheim International GmbH $41,151.00 08/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713316
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 08/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713318
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 08/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713320
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 08/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713322
Principal investigator 1 Boehringer Ingelheim International GmbH $3,900.00 08/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713324
Principal investigator 1 Boehringer Ingelheim International GmbH $670.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713312
Principal investigator 1 Boehringer Ingelheim International GmbH $27,434.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713498
Principal investigator 1 Boehringer Ingelheim International GmbH $425.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713502
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713504
Principal investigator 1 Boehringer Ingelheim International GmbH $1,040.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713506
Principal investigator 1 Boehringer Ingelheim International GmbH $3,770.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713508
Principal investigator 1 Boehringer Ingelheim International GmbH $670.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713510
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713512
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713514
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713516
Principal investigator 1 Boehringer Ingelheim International GmbH $22,011.00 07/30/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713520
Principal investigator 1 Boehringer Ingelheim International GmbH $207.38 07/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713522
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 07/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713524
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 07/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713526
Principal investigator 1 Boehringer Ingelheim International GmbH $72.00 07/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713528
Principal investigator 1 Boehringer Ingelheim International GmbH $2.92 07/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713530
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 07/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713532
Principal investigator 1 Boehringer Ingelheim International GmbH $11.32 07/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713534
Principal investigator 1 Boehringer Ingelheim International GmbH $190.50 07/22/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713536
Principal investigator 1 Boehringer Ingelheim International GmbH $27,434.00 07/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713304
Principal investigator 1 Boehringer Ingelheim International GmbH $14,674.00 07/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713306
Principal investigator 1 Boehringer Ingelheim International GmbH $14,674.00 07/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713496
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713500
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 07/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713518
Principal investigator 1 Boehringer Ingelheim International GmbH $1,040.00 07/11/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713310
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/10/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713308
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/10/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713314
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713538
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 06/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713300
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 06/24/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713302
Principal investigator 1 Boehringer Ingelheim International GmbH $39,732.00 06/20/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713290
Principal investigator 1 Boehringer Ingelheim International GmbH $20,339.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713282
Principal investigator 1 Boehringer Ingelheim International GmbH $10,879.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713284
Principal investigator 1 Boehringer Ingelheim International GmbH $21,252.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713286
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713288
Principal investigator 1 Boehringer Ingelheim International GmbH $2,405.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713294
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713296
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713298
Principal investigator 1 Boehringer Ingelheim International GmbH $10,879.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713422
Principal investigator 1 Boehringer Ingelheim International GmbH $21,252.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713426
Principal investigator 1 Boehringer Ingelheim International GmbH $20,339.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713434
Principal investigator 1 Boehringer Ingelheim International GmbH $39,732.00 06/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713452
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713280
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713292
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713420
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713424
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713428
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713430
Principal investigator 1 Boehringer Ingelheim International GmbH $2,405.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713432
Principal investigator 1 Boehringer Ingelheim International GmbH $535.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713436
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713438
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713440
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713442
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713444
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713446
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713448
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/13/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713450
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713548
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 05/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713494
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713454
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713456
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713458
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713460
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713462
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713464
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713466
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713468
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713470
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713472
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713474
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713476
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713478
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713480
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/16/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713482
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713484
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 05/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713486
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 04/23/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713488
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713490
Principal investigator 1 Boehringer Ingelheim International GmbH $29.31 04/23/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713492
Principal investigator 1 Boehringer Ingelheim International GmbH $13,409.00 04/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713408
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 04/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713410
Principal investigator 1 Boehringer Ingelheim International GmbH $4,290.00 04/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713412
Principal investigator 1 Boehringer Ingelheim International GmbH $25,069.00 04/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713416
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 04/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713418
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713406
Principal investigator 1 Boehringer Ingelheim International GmbH $3,900.00 03/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713260
Principal investigator 1 Boehringer Ingelheim International GmbH $13,409.00 03/26/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713262
Principal investigator 1 Boehringer Ingelheim International GmbH $25,069.00 03/26/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713264
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 03/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713266
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 03/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713268
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 03/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713402
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 03/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713404
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713414
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713254
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713256
Principal investigator 1 Boehringer Ingelheim International GmbH $10,879.00 02/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713258
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713384
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/27/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713396
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713270
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713272
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713274
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713276
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713278
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 02/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713398
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 02/25/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713400
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/19/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713392
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/19/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713394
Principal investigator 1 Boehringer Ingelheim International GmbH $9,933.00 02/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713248
Principal investigator 1 Boehringer Ingelheim International GmbH $13,244.00 02/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713250
Principal investigator 1 Boehringer Ingelheim International GmbH $9,815.00 02/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220713252
Principal investigator 1 Boehringer Ingelheim International GmbH $9,933.00 02/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713382
Principal investigator 1 Boehringer Ingelheim International GmbH $9,945.00 02/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713386
Principal investigator 1 Boehringer Ingelheim International GmbH $7,084.00 02/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713388
Principal investigator 1 Boehringer Ingelheim International GmbH $13,244.00 02/03/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713390
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713546
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,971.60 01/29/2025 Non-covered Recipient Entity
ELEVATE CLINICAL RESEARCH INC.
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185541326
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Centex Studies Inc
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220713380